A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma
| Autor: | Joanne E. Mortimer, Patrick J. Loehrer, René Gonin, Kathy D. Miller, William Pletcher, C. H. Spiridonidis, George Weber, Rafat Ansari, John McClean |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Male medicine.medical_specialty Carcinoma Hepatocellular Pancreatic disease medicine.medical_treatment Phases of clinical research Adenocarcinoma Gastroenterology Zidovudine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) Aged Pharmacology Chemotherapy business.industry Liver Neoplasms Remission Induction Middle Aged medicine.disease Surgery Pancreatic Neoplasms Regimen Methotrexate Oncology Hepatocellular carcinoma Female business medicine.drug |
| Zdroj: | Investigational New Drugs. 14:207-212 |
| ISSN: | 1573-0646 0167-6997 |
| Popis: | From January 1992 through May 1993, 31 patients with adenocarcinoma of the pancreas or hepatocellular carcinoma were treated with weekly oral methotrexate (7.5 mg/M2 every 6 hours for 6 doses) and continuous oral AZT (200 mg four times daily). Patients were treated for a total of 6 months or until disease progression. The median age was 66 (range 44-79) and the median KPS was 80. No patient had received prior chemotherapy. Hematologic toxicity was severe with 50% of patients developing hemoglobins less than 8 gm/dl and 70% with granulocyte counts less than 1000 per mm3. One patient achieved a radiographic complete remission and 2 had stable disease. Two-thirds of patients progressed within 2 months of beginning therapy. The combination of methotrexate and AZT is an inactive regimen in pancreatic and hepatocellular carcinoma and is associated with considerable toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink